(Q37800110)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20946091%20AND%20SRC:MED&resulttype=core&format=json

15 February 2020

title

Tumor vasculature as target for therapeutic intervention (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20946091%20AND%20SRC:MED&resulttype=core&format=json

15 February 2020

author

Raymond M. Schiffelers

series ordinal

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20946091%20AND%20SRC:MED&resulttype=core&format=json

15 February 2020

author name string

Marcel H A M Fens

series ordinal

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20946091%20AND%20SRC:MED&resulttype=core&format=json

15 February 2020

Gert Storm

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20946091%20AND%20SRC:MED&resulttype=core&format=json

15 February 2020

language of work or name

English

0 references

publication date

15 October 2010

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20946091%20AND%20SRC:MED&resulttype=core&format=json

Expert Opinion on Investigational Drugs

15 February 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20946091%20AND%20SRC:MED&resulttype=core&format=json

15 February 2020

volume

19

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20946091%20AND%20SRC:MED&resulttype=core&format=json

15 February 2020

issue

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20946091%20AND%20SRC:MED&resulttype=core&format=json

15 February 2020

page(s)

1321-1338

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20946091%20AND%20SRC:MED&resulttype=core&format=json

A genetic model for colorectal tumorigenesis

15 February 2020

cites work

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.524204

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.524204

Angiogenesis in cancer and other diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.524204

Angiogenesis in health and disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.524204

Tumour vascularization: sprouting angiogenesis and beyond

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.524204

Selective ablation of immature blood vessels in established human tumors follows vascular endothelial growth factor withdrawal

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.524204

Cellular abnormalities of blood vessels as targets in cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.524204

Tumour vascular targeting

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.524204

Intravital imaging of tumour vascular networks using multi-photon fluorescence microscopy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.524204

Openings between defective endothelial cells explain tumor vessel leakiness

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.524204

Endothelial cells of tumor vessels: abnormal but not absent.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.524204

Regulation of transport pathways in tumor vessels: role of tumor type and microenvironment

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.524204

Dissecting tumour pathophysiology using intravital microscopy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.524204

Specialization of tumour vasculature

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.524204

Angiogenesis in life, disease and medicine

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.524204

Tumor angiogenesis: therapeutic implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.524204

Synthetic analogues of fumagillin that inhibit angiogenesis and suppress tumour growth

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.524204

Genes that distinguish physiological and pathological angiogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.524204

Friends or foes - bipolar effects of the tumour stroma in cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.524204

Basement membranes: structure, assembly and role in tumour angiogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.524204

Abnormalities in pericytes on blood vessels and endothelial sprouts in tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.524204

21 January 2018

Fibroblasts in cancer

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.524204

Origin of carcinoma associated fibroblasts

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.524204

Cancer-related inflammation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.524204

Inflammation: gearing the journey to cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.524204

Macrophages: Obligate Partners for Tumor Cell Migration, Invasion, and Metastasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.524204

Distinct role of macrophages in different tumor microenvironments

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.524204

Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.524204

Molecular regulation of vessel maturation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.524204

Tumorigenesis and the angiogenic switch

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.524204

The biology of VEGF and its receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.524204

VEGF as a key mediator of angiogenesis in cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.524204

Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.524204

The role of alphav integrins during angiogenesis: insights into potential mechanisms of action and clinical development.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.524204

Involvement of integrin alpha V gene expression in human melanoma tumorigenicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.524204

Requirement of vascular integrin alpha v beta 3 for angiogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.524204

Imaging of angiogenesis: from microscope to clinic

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.524204

Antiintegrin alpha v beta 3 blocks human breast cancer growth and angiogenesis in human skin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.524204

Integrin alpha v beta 3 antagonists promote tumor regression by inducing apoptosis of angiogenic blood vessels

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.524204

Extensive vasculogenesis, angiogenesis, and organogenesis precede lethality in mice lacking all alpha v integrins

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.524204

Endogenous inhibitors of angiogenesis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.524204

The contribution of vascular basement membranes and extracellular matrix to the mechanics of tumor angiogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.524204

Endogenous inhibitors of angiogenesis: a historical review

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.524204

Vascular attack as a therapeutic strategy for cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.524204

Endothelial cell proliferation as a novel approach to targeting tumour therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.524204

Angiogenesis as a therapeutic target

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.524204

The anti-angiogenic basis of metronomic chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.524204

Metastases and the normalization of tumour blood vessels by ICRF 159: a new type of drug action

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.524204

Dynamics of tumour angiogenesis: effect of razoxane-induced growth rate slowdown

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.524204

Normalizing tumor vasculature with anti-angiogenic therapy: a new paradigm for combination therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.524204

Effect of antivascular endothelial growth factor treatment on the intratumoral uptake of CPT-11.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.524204

VEGF-targeted cancer therapy strategies: current progress, hurdles and future prospects

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.524204

Complete pathological response to bevacizumab and chemoradiation in advanced rectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.524204

The pathophysiology of tumor necrosis factors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.524204

Low-dose tumor necrosis factor-alpha augments antitumor activity of stealth liposomal doxorubicin (DOXIL) in soft tissue sarcoma-bearing rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.524204

Tumor necrosis factor alpha mediates homogeneous distribution of liposomes in murine melanoma that contributes to a better tumor response

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.524204

Early destruction of tumor vasculature in tumor necrosis factor-alpha-based isolated limb perfusion is responsible for tumor response

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.524204

Synergistic antitumor activity of histamine plus melphalan in isolated limb perfusion: preclinical studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.524204

Synergistic antitumor response of interleukin 2 with melphalan in isolated limb perfusion in soft tissue sarcoma-bearing rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.524204

Technology insight: Utility of TNF-alpha-based isolated limb perfusion to avoid amputation of irresectable tumors of the extremities

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.524204

Isolated limb perfusion with melphalan and TNF-alpha in the treatment of extremity sarcoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.524204

Disrupting tumour blood vessels

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.524204

Dynamic instability of microtubule growth

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.524204

Microtubule depolymerization rapidly collapses capillary tube networks in vitro and angiogenic vessels in vivo through the small GTPase Rho.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.524204

Tumour targeting by microtubule-depolymerizing vascular disrupting agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.524204

Vascular targeting agents as cancer therapeutics

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.524204

Enhancement of radiation therapy by the novel vascular targeting agent ZD6126.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.524204

Vascular targeting agents enhance chemotherapeutic agent activities in solid tumor therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.524204

The vascular disrupting agent ZD6126 shows increased antitumor efficacy and enhanced radiation response in large, advanced tumors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.524204

Adverse effects of anticancer agents that target the VEGF pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.524204

Phase I clinical evaluation of weekly administration of the novel vascular-targeting agent, ZD6126, in patients with solid tumors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.524204

Resistance to antiangiogenic therapy is directed by vascular phenotype, vessel stabilization, and maturation in malignant melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.524204

How an agonist peptide mimics the antibiotic tetracycline to induce Tet-repressor

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.524204

Phase II study of recombinant human endostatin in patients with advanced neuroendocrine tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.524204

Endostatins derived from collagens XV and XVIII differ in structural and binding properties, tissue distribution and anti-angiogenic activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.524204

Distinct antitumor properties of a type IV collagen domain derived from basement membrane

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.524204

Tumor progression: the effects of thrombospondin-1 and -2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.524204

Canstatin, a novel matrix-derived inhibitor of angiogenesis and tumor growth

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.524204

Endorepellin, a novel inhibitor of angiogenesis derived from the C terminus of perlecan

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.524204

Pigment epithelium-derived factor: a potent inhibitor of angiogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.524204

Recombinant human angiostatin (rhAngiostatin) in combination with paclitaxel and carboplatin in patients with advanced non-small-cell lung cancer: a phase II study from Indiana University.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.524204

Antiangiogenic activity of the cleaved conformation of the serpin antithrombin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.524204

Prothrombin kringle-2 domain has a growth inhibitory activity against basic fibroblast growth factor-stimulated capillary endothelial cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.524204

Inhibition of Angiogenesis by Recombinant Human Platelet Factor-4 and Related Peptides

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.524204

Specific loss of chondromodulin-I gene expression in chondrosarcoma and the suppression of tumor angiogenesis and growth by its recombinant protein in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.524204

Matrix Metalloproteinase Inhibitors and Cancer--Trials and Tribulations

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.524204

Novel therapy with 2-methoxyestradiol for the treatment of relapsed and plateau phase multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.524204

Vasostatin, a calreticulin fragment, inhibits angiogenesis and suppresses tumor growth

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.524204

AEE788: a dual family epidermal growth factor receptor/ErbB2 and vascular endothelial growth factor receptor tyrosine kinase inhibitor with antitumor and antiangiogenic activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.524204

Phase I clinical trial of cilengitide in children with refractory brain tumors: Pediatric Brain Tumor Consortium Study PBTC-012.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.524204

Randomized phase II study of cilengitide, an integrin-targeting arginine-glycine-aspartic acid peptide, in recurrent glioblastoma multiforme

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.524204

Phase III trial of FOLFOX plus bevacizumab or cediranib (AZD2171) as first-line treatment of patients with metastatic colorectal cancer: HORIZON III.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.524204

Randomized phase II study of vandetanib alone or with paclitaxel and carboplatin as first-line treatment for advanced non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.524204

The clinical benefit of bevacizumab in metastatic colorectal cancer is independent of K-ras mutation status: analysis of a phase III study of bevacizumab with chemotherapy in previously untreated metastatic colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.524204

Phase III trial of cisplatin plus gemcitabine with either placebo or bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer: AVAil

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.524204

Combined vascular endothelial growth factor-targeted therapy and radiotherapy for rectal cancer: theory and clinical practice

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.524204

Axitinib is an active treatment for all histologic subtypes of advanced thyroid cancer: results from a phase II study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.524204

Phase I trial of a monoclonal antibody specific for alphavbeta3 integrin (MEDI-522) in patients with advanced malignancies, including an assessment of effect on tumor perfusion

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.524204

Phase I and pharmacokinetic study of etaracizumab (Abegrin), a humanized monoclonal antibody against alphavbeta3 integrin receptor, in patients with advanced solid tumors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.524204

Volociximab, a chimeric monoclonal antibody that specifically binds alpha5beta1 integrin: a phase I, pharmacokinetic, and biological correlative study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.524204

Inhibition of Dll4 signalling inhibits tumour growth by deregulating angiogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.524204

Sunitinib versus interferon alfa in metastatic renal-cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.524204

Histamine, a vasoactive agent with vascular disrupting potential, improves tumour response by enhancing local drug delivery

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.524204

Synergistic antitumor effects of histamine plus melphalan in isolated hepatic perfusion for liver metastases

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.524204

ZD6126: a novel small molecule vascular targeting agent

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.524204

Phase I clinical evaluation of ZD6126, a novel vascular-targeting agent, in patients with solid tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.524204

Phase I clinical trial of weekly combretastatin A4 phosphate: clinical and pharmacokinetic results

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.524204

Differential relationship between changes in tumour size and microcirculatory functions induced by therapy with an antivascular drug and with cytotoxic drugs. implications for the evaluation of therapeutic efficacy of AC7700 (AVE8062).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.524204

Comparative preclinical pharmacokinetic and metabolic studies of the combretastatin prodrugs combretastatin A4 phosphate and A1 phosphate

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.524204

Randomised phase II study of ASA404 combined with carboplatin and paclitaxel in previously untreated advanced non-small cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.524204

Small molecule vascular disrupting agents: potential new drugs for cancer treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.524204

A phase 1 study of ABT-751, an orally bioavailable tubulin inhibitor, administered daily for 7 days every 21 days in pediatric patients with solid tumors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.524204

Disruption of angiogenesis by PEX, a noncatalytic metalloproteinase fragment with integrin binding activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.524204

Roles of prolactin and related members of the prolactin/growth hormone/placental lactogen family in angiogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.524204

Troponin I is present in human cartilage and inhibits angiogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.524204

AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.524204

Phase I dose escalation study of telatinib (BAY 57-9352) in patients with advanced solid tumours

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.524204

Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.524204

Lack of efficacy of Doxil in TNF-alpha-based isolated limb perfusion in sarcoma-bearing rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.524204

Tumor necrosis factor-alpha augments tumor effects in isolated hepatic perfusion with melphalan in a rat sarcoma model

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.524204

Tumor necrosis factor-alpha augmented tumor response in B16BL6 melanoma-bearing mice treated with stealth liposomal doxorubicin (Doxil) correlates with altered Doxil pharmacokinetics

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.524204

Addition of low-dose tumor necrosis factor-alpha to systemic treatment with STEALTH liposomal doxorubicin (Doxil) improved anti-tumor activity in osteosarcoma-bearing rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.524204

Pegylated liposomal tumor necrosis factor-alpha results in reduced toxicity and synergistic antitumor activity after systemic administration in combination with liposomal doxorubicin (Doxil) in soft tissue sarcoma-bearing rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.524204

Antitumor effects of liposomal IL1? and TNF? against the pulmonary metastases of the B16F10 murine melanoma in syngeneic mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.524204

Enhancement of tumor necrosis factor alpha antitumor immunotherapeutic properties by targeted delivery to aminopeptidase N (CD13).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.524204

Improving chemotherapeutic drug penetration in tumors by vascular targeting and barrier alteration

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.524204

Synergistic damage of tumor vessels with ultra low-dose endothelial-monocyte activating polypeptide-II and neovasculature-targeted tumor necrosis factor-alpha

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.524204

Coupling tumor necrosis factor-alpha with alphaV integrin ligands improves its antineoplastic activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.524204

NPI-2358 is a tubulin-depolymerizing agent: in-vitro evidence for activity as a tumor vascular-disrupting agent

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.524204

MPC-6827: a small-molecule inhibitor of microtubule formation that is not a substrate for multidrug resistance pumps

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.524204

A phase 2 clinical study of SU5416 in patients with refractory acute myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.524204

10.1517/13543784.2010.524204

21 January 2018

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20946091%20AND%20SRC:MED&resulttype=core&format=json

15 February 2020

1 reference